JPH09501571A - モノクローナル抗体 - Google Patents
モノクローナル抗体Info
- Publication number
- JPH09501571A JPH09501571A JP7507411A JP50741195A JPH09501571A JP H09501571 A JPH09501571 A JP H09501571A JP 7507411 A JP7507411 A JP 7507411A JP 50741195 A JP50741195 A JP 50741195A JP H09501571 A JPH09501571 A JP H09501571A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- cea
- residues
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.VH鎖の配列が、 あるいはVH鎖の配列が、VHCDR1の最初のアミノ酸残基がグルタミンである こと以外は上と同じであり、どちらの場合でもVL鎖の配列が であるIgG1グループIIA重鎖とκグループV軽鎖とを備える完全なマウス モノクローナル抗体以外の分子であって、 (i)膜結合性ヒト癌胎児性抗原を結合し、(ii)ヒト癌胎児性抗原の490 残基〜C末端に結合(N−C)したヒトの胆汁糖タンパク質の1〜314残基か らなるハイブリッドポリペプチドを結合し、かつ(iii)ヒトの胆汁糖タンパク 質に結合しない分子。 2.ヒトフレームワーク領域と、請求項1に記載されたVH鎖とVL鎖の少なくと も一つの相補性決定領域を有する抗体であって、VH鎖のCDR1がVFGMN 、CDR2がWINTKTGEATYVEEFKGおよびCDR3がWDFYD YVEAMDYであり、VL鎖のCDR1がKASQNVGTNVA、CDR2 がSASYRYSおよびCDR3がHQYYTYPLFTとされた抗体である請 求項1記載の分子。 3.抗体がモノクローナル抗体である請求項2記載の分子。 4.さらに直接的または間接的な細胞毒性分子を備えた請求項1ないし3のいず れか一項に記載の分子。 5.さらに容易に検出可能な標識を備えた請求項1ないし3のいずれか一項に記 載の分子。 6.医薬に用いるための請求項1ないし5のいずれか一項に記載の分子。 7.結腸直腸癌腫の診断に使用される医薬の製造における請求項1ないし3およ び5のいずれか一項に記載の分子の使用。 8.結腸直腸癌腫の治療に使用される医薬の製造における請求項1ないし4のい ずれか一項に記載の分子の使用。 9.(i)ヒト癌胎児性抗原を結合し、(ii)ヒト癌胎児性抗原の490残基〜 C末端に結合(N−C)したヒトの胆汁糖タンパク質の1〜314残基からなる ハィブリッドポリペプチドを結合し、かつ(iii)ヒトの胆汁糖タンパク質に結 合しない単一特異的抗体を選択するように、抗体のプールをスクリーニングする ことを含む単一特異的抗体の製造方法。 10.単一特異的抗体がモノクローナル抗体であり、抗体のプールがモノクロー ナル抗体のプールである請求項9記載の方法。 11.プール内の抗体が、組換えDNA方法によって製造された抗体である請求 項9記載の方法。 12.抗体の結合部位が、レプリカベクターの表面に提示される請求項11記載 の方法。 13.レプリカベクターがバクテリオファージである請求項12記載の方法。 14.請求項9ないし13のいずれか一項の方法によって得られる単一特異的抗 体。 15.ヒト癌胎児性抗原の490残基〜C末端に結合(N−C)したヒトの胆汁 糖タンパク質の1〜314残基からなるハイブリッドポリペプチド。 16.ヒト癌胎児性抗原の490〜643残基に結合(N−C)したヒトの胆汁 糖タンパク質の1〜314残基からなるハイブリッドポリペプチド。 17.ヒトの胆汁糖タンパク質の1〜314残基、ヒト癌胎児性抗原の490〜 644残基、ヒトの胆汁糖タンパク質の391〜430残基の順で結合(N−C )したハイブリッドポリペプチド。 18.ヒトの胆汁糖タンパク質の1〜314残基、ヒト癌胎児性抗原の490〜 642残基、ヒトの胆汁糖タンパク質の387〜430残基の順で結合(N−C )したハイブリッドポリペプチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939317423A GB9317423D0 (en) | 1993-08-21 | 1993-08-21 | Monoclonal antibodies |
GB9317423.3 | 1993-08-21 | ||
PCT/GB1994/001816 WO1995006067A1 (en) | 1993-08-21 | 1994-08-19 | Monoclonal antibodies for use in diagnosis and treatment of colorectal cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09501571A true JPH09501571A (ja) | 1997-02-18 |
JP3492373B2 JP3492373B2 (ja) | 2004-02-03 |
Family
ID=10740834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50741195A Expired - Lifetime JP3492373B2 (ja) | 1993-08-21 | 1994-08-19 | モノクローナル抗体 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5965710A (ja) |
EP (1) | EP0721470B1 (ja) |
JP (1) | JP3492373B2 (ja) |
AT (1) | ATE226596T1 (ja) |
AU (1) | AU7390694A (ja) |
CA (1) | CA2168440C (ja) |
DE (1) | DE69431602T2 (ja) |
DK (1) | DK0721470T3 (ja) |
ES (1) | ES2187529T3 (ja) |
GB (1) | GB9317423D0 (ja) |
PT (1) | PT721470E (ja) |
WO (1) | WO1995006067A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013505732A (ja) * | 2009-09-29 | 2013-02-21 | ロシュ グリクアート アーゲー | 二重特異性デス受容体アゴニスト抗体 |
JP2014509200A (ja) * | 2011-03-02 | 2014-04-17 | ロシュ グリクアート アーゲー | Cea抗体 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5872215A (en) * | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
GB9621295D0 (en) * | 1995-12-07 | 1996-11-27 | Cambridge Antibody Tech | Specific binding members,materials and methods |
US6417337B1 (en) * | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
EP1007967A2 (en) * | 1997-08-04 | 2000-06-14 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
DE19739685A1 (de) * | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
AU6940700A (en) * | 1999-08-26 | 2001-03-19 | Amy P. N Skubitz | Peptides capable of modulating the function of cd66 (ceacam) family members |
US6835549B2 (en) * | 2000-02-24 | 2004-12-28 | University Of Medicine & Dentistry Of New Jersey | Immunoassay method for the diagnosis of gastric intestinal metaplasia associated with gastric carcinoma |
US6774209B1 (en) | 2000-04-03 | 2004-08-10 | Dyax Corp. | Binding peptides for carcinoembryonic antigen (CEA) |
WO2002068601A2 (en) * | 2001-02-28 | 2002-09-06 | Skubitz Keith M | Small peptides capable of modulating the function of cd66 (ceacam) family members |
US7101663B2 (en) * | 2001-03-02 | 2006-09-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | PCR method |
KR100607612B1 (ko) * | 2001-06-20 | 2006-08-02 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
CA2517908A1 (en) * | 2003-03-04 | 2005-02-10 | Auburn University | Methods of forming monolayers of phage-derived products and uses thereof |
WO2005114444A1 (en) * | 2004-04-30 | 2005-12-01 | America Online, Inc. | Network configuration management |
US8187595B2 (en) | 2004-05-07 | 2012-05-29 | The University Of North Carolina At Chapel Hill | Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I |
AU2005286876A1 (en) * | 2004-09-20 | 2006-03-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Multiple mode multiplex reaction quenching method |
CA2618796C (en) | 2005-08-11 | 2018-01-02 | Arpi Matossian-Rogers | Peptides for treatment and diagnosis of autoimmune disease |
EP1940355B1 (en) | 2005-09-30 | 2012-12-19 | Auburn University | Targeted drug delivery nanocarrier comprising a targeting landscape phage protein assembly |
US8119352B2 (en) * | 2006-06-20 | 2012-02-21 | Cepheld | Multi-stage amplification reactions by control of sequence replication times |
ES2392089T3 (es) * | 2008-02-29 | 2012-12-04 | Endosignals Imaging Gmbh | Fragmentos de adhesina optimizados y nanopartículas correspondientes |
EP2473532B1 (en) * | 2009-08-31 | 2017-06-21 | Roche Glycart AG | Affinity-matured humanized anti cea monoclonal antibodies |
US10126216B2 (en) | 2011-02-17 | 2018-11-13 | Ventana Medical Systems, Inc. | Method for tissue sample fixation |
US10539487B2 (en) | 2010-03-04 | 2020-01-21 | Ventana Medical Systems, Inc. | Systems and methods for monitoring tissue sample processing |
JP5732078B2 (ja) | 2010-03-04 | 2015-06-10 | ベンタナ メディカル システムズ, インコーポレイテッド | 音響エネルギーを使用して標本を処理するための処理システム |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
EP2890716A4 (en) | 2012-08-31 | 2016-06-08 | Univ North Carolina | MONOCLONAL ANTIBODIES INCREASING OR INHIBITING INSULIN-1 GROWTH FACTOR (IGF-1) |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
US9753036B2 (en) | 2014-04-29 | 2017-09-05 | Edp Biotech Corporation | Methods and compositions for screening and detecting biomarkers |
WO2023180489A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU625613B2 (en) * | 1988-01-05 | 1992-07-16 | Novartis Ag | Novel chimeric antibodies |
-
1993
- 1993-08-21 GB GB939317423A patent/GB9317423D0/en active Pending
-
1994
- 1994-08-19 DK DK94923816T patent/DK0721470T3/da active
- 1994-08-19 WO PCT/GB1994/001816 patent/WO1995006067A1/en active IP Right Grant
- 1994-08-19 US US08/602,725 patent/US5965710A/en not_active Expired - Lifetime
- 1994-08-19 AU AU73906/94A patent/AU7390694A/en not_active Withdrawn
- 1994-08-19 PT PT94923816T patent/PT721470E/pt unknown
- 1994-08-19 JP JP50741195A patent/JP3492373B2/ja not_active Expired - Lifetime
- 1994-08-19 ES ES94923816T patent/ES2187529T3/es not_active Expired - Lifetime
- 1994-08-19 EP EP94923816A patent/EP0721470B1/en not_active Expired - Lifetime
- 1994-08-19 DE DE69431602T patent/DE69431602T2/de not_active Expired - Lifetime
- 1994-08-19 AT AT94923816T patent/ATE226596T1/de active
- 1994-08-19 CA CA002168440A patent/CA2168440C/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013505732A (ja) * | 2009-09-29 | 2013-02-21 | ロシュ グリクアート アーゲー | 二重特異性デス受容体アゴニスト抗体 |
JP2014509200A (ja) * | 2011-03-02 | 2014-04-17 | ロシュ グリクアート アーゲー | Cea抗体 |
Also Published As
Publication number | Publication date |
---|---|
ATE226596T1 (de) | 2002-11-15 |
EP0721470A1 (en) | 1996-07-17 |
WO1995006067A1 (en) | 1995-03-02 |
DK0721470T3 (da) | 2003-02-24 |
JP3492373B2 (ja) | 2004-02-03 |
GB9317423D0 (en) | 1993-10-06 |
PT721470E (pt) | 2003-03-31 |
DE69431602D1 (de) | 2002-11-28 |
US5965710A (en) | 1999-10-12 |
EP0721470B1 (en) | 2002-10-23 |
ES2187529T3 (es) | 2003-06-16 |
DE69431602T2 (de) | 2003-06-26 |
CA2168440C (en) | 2002-07-23 |
AU7390694A (en) | 1995-03-21 |
CA2168440A1 (en) | 1995-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3492373B2 (ja) | モノクローナル抗体 | |
JP4124486B2 (ja) | ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用 | |
CA2020247C (en) | Antibodies reactive with human carcinomas | |
JP5028635B2 (ja) | Fzd10に対する腫瘍標的化モノクローナル抗体とその使用 | |
FI109207B (fi) | Tuumori/hiilihydraattiantigeenispesifinen monoklonaalinen vasta-aine ja solulinja | |
RU2204606C2 (ru) | Антитело vff-18 и его аналоги | |
US7183384B2 (en) | Monoclonal antibody 7H11 reactive with human cancer | |
JP2935520B2 (ja) | ガン治療に用いられる新規高親和性改変抗体系統群 | |
JPH10505749A (ja) | ヒトの結腸がん腫結合抗原に対するモノクローナル抗体とその用法 | |
JP2000511421A5 (ja) | ||
JP2001501801A (ja) | モノクローナル抗体br110およびその使用 | |
CN111777681A (zh) | 一种结合紧密连接蛋白-18.2的抗体及其用途 | |
US11554177B2 (en) | Antibody-drug conjugates targeting human Claudin 18.2 | |
CN109988240A (zh) | 抗gpc-3抗体及其用途 | |
JP4803879B2 (ja) | ヒト化抗−癌腫モノクローナル抗体cc49 | |
US20230002503A1 (en) | Nano-antibody targeting caix antigen and application thereof | |
JP2017024991A (ja) | 抗カドヘリン17抗体及び胃がん体外イメージング剤 | |
KR102090444B1 (ko) | 항-icam4 항체 및 icam4 발현 세포와 관련된 질병의 진단 및 치료용 조성물 | |
RU2816856C2 (ru) | Антитела, нацеленные на epn1 | |
CA2255540C (en) | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers | |
NO316023B1 (no) | Fremgangsmåte for fremstilling av et terapeutisk aktivt antistoff eller etterapeutisk aktivt fragment derav som er selektive for TAG-72 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081114 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091114 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091114 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101114 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111114 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111114 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121114 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121114 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131114 Year of fee payment: 10 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |